Trial reportJournal of thrombosis and thrombolysis2012
Bleeding risk factors associated with argatroban therapy in the critically ill.
Trial report in Journal of thrombosis and thrombolysis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Prognostic factors for patients with heparin-induced thrombocytopenia: a systematic review.International journal of clinical pharmacy · 2021Pooled it
- Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.BMC anesthesiology · 2018Trial
- Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.Critical care (London, England) · 2014Trial
- Computational and Molecular Dynamics Insights into the Antithrombotic Mechanism of Triterpenes Derived fromMolecules (Basel, Switzerland) · 2026Article
- Bleeding outcomes in critically ill patients on heparin with discordant aPTT and anti-Xa activity.Journal of thrombosis and thrombolysis · 2025Article
- Viscoelastic Hemostatic Testing as a Diagnostic Tool for Hypercoagulability in Liver Transplantation: A Narrative Review.Journal of clinical medicine · 2024Review
- Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis.International journal of clinical pharmacy · 2021Review
- Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation.Journal of critical care · 2020Article
- A Prospective Pilot Trial to Assess the Efficacy of Argatroban (ArgatraJournal of clinical medicine · 2020Article
- Two High to Start? Targeting a New Starting Dose for Argatroban Infusions.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2020Article
- Bleeding complications after cardiac surgery, before anticoagulation start and then with argatroban or heparin in the early postoperative setting.Journal of cardiothoracic surgery · 2020Article
- The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia.Journal of thrombosis and haemostasis : JTH · 2019Article
- Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Article
- Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support.Annals of intensive care · 2017Article
- Early initiation of argatroban therapy in the management of acute superior mesenteric venous thrombosis.Experimental and therapeutic medicine · 2017Article
- Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.Journal of cardiothoracic surgery · 2015Article
- The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution.Anaesthesia and intensive care · 2014Article
- Lower argatroban starting dose and lower aPTT goal range instead of aggressive monitoring.Journal of thrombosis and thrombolysis · 2013Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Argatroban is a parenteral direct thrombin inhibitor labeled for anticoagulation in patients with confirmed or suspected heparin-induced thrombocytopenia in the United States. Currently there are no studies evaluating bleeding risk factors in Intensive Care Unit patients.To determine bleeding risk factors associated with argatroban therapy in the critically ill. Critically ill patients admitted between July 2007-June 2008 who received argatroban were included in this retrospective cohort study. The primary endpoint was the incidence of bleeding complications associated with argatroban. Major bleeding was defined as a hemoglobin reduction ≥2 g/dL plus a transfusion of ≥2 units of blood in a 24 h period, or a retroperitoneal, intracranial, prosthetic joint, or other life-threatening bleed. Minor bleeding was any overt bleeding not fitting the major bleeding definition. Secondary outcomes included identifying risk factors for bleeding. Seventy-three patients were included with 16 (21.9%) total bleeding complications, 7 (9.6%) major and 9 (12.3%) minor bleeds. Four risk factors for bleeding were identified by univariate analysis: major surgery prior to or during argatroban therapy (OR = 8.4, 95% CI: 2.3-30.1, p = 0.001), dosing weight >90 kg (OR = 4.8, 95% CI: 1.4-15.8, p = 0.01), total bilirubin >3 mg/dL (OR = 8.1, 95% CI: 2.1-31.1, p = 0.002), and baseline platelets ≤70 K/μL (OR = 4.2, 95 % CI: 1.1-16.3, p = 0.039).Risks and benefits of argatroban should be weighed in patients with major surgery prior to or during argatroban, dosing weight ≥90 kg, total bilirubin ≥3 mg/dL, and baseline platelets ≤70 K/μL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.